Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
IPO Year: 2018
Exchange: NYSE
Website: elanco.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/17/2025 | $18.00 | Market Perform → Outperform | Leerink Partners |
| 6/26/2025 | Mkt Perform → Outperform | William Blair | |
| 12/9/2024 | $18.00 | Buy | UBS |
| 12/2/2024 | $14.00 | Market Perform | Leerink Partners |
| 9/19/2024 | $17.00 → $15.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2024 | $13.00 → $20.00 | Hold → Buy | Stifel |
| 12/19/2023 | $17.00 | Buy | Jefferies |
| 12/15/2023 | $16.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/7/2023 | $18.00 | Outperform | Exane BNP Paribas |
| 4/20/2023 | $14.00 | Equal Weight → Overweight | Barclays |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Leerink Partners upgraded Elanco Animal Health from Market Perform to Outperform and set a new price target of $18.00
William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform
UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00
Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00
Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously
Stifel upgraded Elanco Animal Health from Hold to Buy and set a new price target of $20.00 from $13.00 previously
Jefferies initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $17.00
Morgan Stanley upgraded Elanco Animal Health from Equal-Weight to Overweight and set a new price target of $16.00
Exane BNP Paribas initiated coverage of Elanco Animal Health with a rating of Outperform and set a new price target of $18.00
Barclays upgraded Elanco Animal Health from Equal Weight to Overweight and set a new price target of $14.00
144 - Elanco Animal Health Inc (0001739104) (Subject)
10-Q - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
SD - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
10-Q - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
DEFA14A - Elanco Animal Health Inc (0001739104) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
Live finance-specific insights
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported
GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported
GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau
GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr
GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily
GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming daysGREENFIELD, Ind., Sept. 19, 2024 /PRNewswire/ -- Elanco Anim
GREENFIELD, Ind., July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/def
First Quarter 2024 Financial ResultsRevenue of $1,205 millionReported Net income of $32 million, Adjusted Net income of $167 millionAdjusted EBITDA of $294 million, or 24.4% of RevenueReported EPS of $0.06, Adjusted EPS of $0.34 Net leverage ratio of 6.1x Adjusted EBITDAYear over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates:Revenue of $4,460 to $4,515 million, con
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
3 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
Live Leadership Updates
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are
GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora
GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,
Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus GREENFIELD, Ind., Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo). The Defend Puppies. Defeat Parvo. mission seeks to conquer a virus that, without timely and aggressive care, has a mortality rate as high as 91%1. An estimated 900 dogs are diagnosed with parvo daily2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know
Ziff Davis, Inc. (NASDAQ:ZD), today announced the appointment of Kirk McDonald to its Board of Directors, effective November 15, 2023. McDonald is a highly accomplished executive with extensive experience and a career spanning more than three decades in media, technology, and advertising. "We are thrilled to welcome Kirk to our Board of Directors," said Ziff Davis Board Chair Sarah Fay. "As an industry veteran known for his business leadership, he will be an asset to Ziff Davis." McDonald serves as CEO of GroupM North America, a leading media investment agency. He announced that he will leave the role at year end. Prior to this, he was Chief Business Officer of Warner Media's Xandr when
Tim Bettington joins Elanco as EVP Corporate Strategy and Market Development Elanco Animal Health (NYSE:ELAN) announced today the appointment of Tim Bettington as the company's executive vice president Corporate Strategy and Market Development. He will join Elanco's executive committee on March 20. As Elanco shifts from the separation and stand up of the independent company and the integration of the Bayer Animal Health acquisition to an increasing focus on delivering its next era of innovation and growth, Bettington's expertise complements the company's existing commercial leadership team. In his role, Bettington will be responsible for corporate strategy and market development, focused
TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po
Pietro Satriano Steps Down as CEO and Will Not Stand for Re-election as Director at 2022 Annual Meeting of Shareholders Robert M. Dutkowsky to Serve as Executive Chair and Andrew Iacobucci to Serve as Interim CEO Board Has Commenced Search for Permanent CEO Appoints James J. Barber, Jr., Scott D. Ferguson and David A. Toy to Board Pursuant to Agreement with Sachem Head Reaffirms Fiscal Year 2022 Guidance US Foods Holding Corp. (NYSE:USFD) ("US Foods" or the "Company"), one of the largest foodservice distributors in the United States, today announced a transition of its Chief Executive Officer. The Company also announced changes to its Board of Directors in connection with a cooperation
Fastest customizable press release news feed in the world
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported
The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the worldLaunch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission. This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia's approval represents a signific
GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8.100% virus neutralization against 33 current field isolates.1Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated dogs post H3N2 challenge.2,3,4TruCan Ultra CIV completes Elanco's extensive line of Tru Portfolio vaccines.GREENFIELD, Ind., July 9, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant MonepantelProvides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processesThe license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 202
GREENFIELD, Ind., June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE:ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them. Reflecting on its purpose and strategic alignment, the report introduces a new framework centered on four key communities of impact, celebrating Elanco's culture of 'Going Beyond' for animals, customers, society, and our people. In launching a new approach to impact reporting, Elanco reaffirms its dedicati
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind., June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing authorization in the European Union in the next 60 days. The positive opinion notes, "The benefits of Zenrelia are its efficacy in the treatment of pruritus associated with allergic dermatiti
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are
GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi
GREENFIELD, Ind., May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, May 22, Jeff Simmons, president and CEO, will participate in the BNP Paribas 2nd Annual Animal Health Day at 12:00 p.m. ET. On Thursday, May 29, Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will participate in a fireside chat at Stifel 2025 Jaws & Paws Conference at 8:00 a.m. ET. Live audio webcasts will be available in the "Events and Presentations" sec
This live feed shows all institutional transactions in real time.
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)